Company intelligence / Profile preview

Protinhi Therapeutics

Nijmegen, Gelderland, Netherlandslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Protinhi Therapeutics has developed proprietary small molecule compounds that inhibit viral proteases essential for viral replication. Their lead programs are in preclinical development and target a range of high-burden viral infections such as dengue and COVID. The company’s approach aims to provide both therapeutic and prophylactic options for these diseases[1][2][6].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (protease inhibitors)
Industry: Biotech

Drug pipeline

1 asset

Geminoid protease inhibitor

Pre-clinical

Indications: Dengue fever, Zika virus infection, West Nile virus infection

Partnerships

Selected as part of the BLUE KNIGHT collaboration for pandemic preparedness—a partnership between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA)

Beyond the preview

Go deeper on Protinhi Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protinhi Therapeutics.

Explore the full profile